Sorafenib (D3)
(Synonyms: 索拉非尼-D3,Bay 43-9006-d3; Donafenib) 目录号 : GC37664An internal standard for the quantification of sorafenib
Cas No.:1130115-44-4
Sample solution is provided at 25 µL, 10mM.
Sorafenib-d3 is intended for use as an internal standard for the quantification of sorafenib by GC- or LC-MS. Sorafenib is a multi-kinase inhibitor that inhibits Raf-1 and B-RAF (IC50s = 6 and 22 ?M, respectively), as well as the receptor tyrosine kinases VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC50s = 90, 15, 20, 57, and 58 nM, respectively).1,2 It is selective for these kinases over 12 other kinases, including ERK1, MEK1, EGFR, and HER2 (IC50s = >10 ?M for all).2 Sorafenib inhibits proliferation of PLC/PRF/5 and HepG2 cells (IC50s = 6.3 and 4.5 ?M, respectively) and induces apoptosis in these cells.3 It completely inhibits tumor growth in a PLC/PRF/5 mouse xenograft model when administered at a dose of 30 mg/kg and reduces basic FGF-induced angiogenesis in a Matrigel? assay in vivo.3,4 Sorafenib (10 ?M) induces ferroptotic cell death in HT-1080 fibrosarcoma cells, an effect that can be blocked by the ferroptosis inhibitors ferrostatin-1 , deferoxamine , and β-mercaptoethanol.5 It inhibits glutamate release by the system xc- cystine/glutamate transporter in HT-1080 cells when used at concentrations ranging from 2.5 to 10 ?M, decreases glutathione levels, and increases lipid peroxidation. Sorafenib also inhibits replication of hepatitis C virus (HCV) in Huh7.5 cells (IC50 = 7.2 ?M).6 Formulations containing sorafenib have been used in the treatment of hepatocellular, renal cell, and thyroid carcinomas.
1.Lyons, J.F., Wilhelm, S., Hibner, B., et al.Discovery of a novel Raf kinase inhibitorEndocr. Relat. Cancer8(3)219-225(2001) 2.Wilhelm, S.M., Carter, C., and Tang, L.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res.64(19)7099-7109(2004) 3.Liu, L., Cao, Y., Chen, C., et al.Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Cancer Res.66(24)11851-11858(2006) 4.Murphy, D.A., Makonnen, S., Lassoued, W., et al.Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006)Am. J. Pathol.169(5)1875-1885(2006) 5.Dixon, S.J., Patel, D.N., Welsch, M., et al.Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosisElife3e02523(2014) 6.Himmelsbach, K., Sauter, D., Baumert, T.F., et al.New aspects of an anti-tumour drug: Sorafenib efficiently inhibits HCV replicationGut58(12)1644-1653(2009)
Cas No. | 1130115-44-4 | SDF | |
别名 | 索拉非尼-D3,Bay 43-9006-d3; Donafenib | ||
Canonical SMILES | O=C(C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C=C2)=C1)NC([2H])([2H])[2H] | ||
分子式 | C21H13D3ClF3N4O3 | 分子量 | 467.84 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1375 mL | 10.6874 mL | 21.3748 mL |
5 mM | 0.4275 mL | 2.1375 mL | 4.275 mL |
10 mM | 0.2137 mL | 1.0687 mL | 2.1375 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet